Clinical Trials Browser

Blood Protein Disorders, Cardiovascular Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Lymphoid, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Recurrence, Vascular Diseases, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Hemostatic Disorders, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell, Dendritic Cell Sarcoma, Interdigitating

Clinical Trials

SUCCESSOR-2

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

MajesTEC-10

A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma

ELISA in Relapsed/Refractory MM

SUCCESSOR-1

LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

KarMMa-2

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

SELVEDge

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

LINKER-MM1

Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma

MagnetisMM-9

QUINTESSENTIAL

MagnetisMM-30

A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma

Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma

MagnetisMM-20

DREAMM-20

A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma

MonumenTAL-3

Mezi-KD

ISABELA

A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

STOMP

GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies

Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

Plan Development for Giving Teclistamab in the Outpatient Setting

DREAMM 13

Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration

Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration

PCD

DC15-MM-01

EMBRACE

INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma

Isa-Pom-Dex in Elderly/Frail Subjects With RRMM

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

DREAMM 14

LINKER-AL2

A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma

A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

ARQ 531-101